TL;DR: Aetna, a CVS Health company, modified CPB 0472 governing thoracic electrical bioimpedance cardiac output monitoring, effective September 26, 2025. If your team bills CPT 93701 for Aetna members, the six covered indications and their documentation requirements define whether you get paid or get denied.
This update to the Aetna thoracic electrical bioimpedance coverage policy tightens the medical necessity framework around CPT 93701. The policy sets six specific indications under which cardiac monitoring via electrical bioimpedance devices is covered — and anything outside those six is not. Review your claim workflows now, before the September 26, 2025 effective date hits your next remittance cycle.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Thoracic Electrical Bioimpedance for Cardiac Output Monitoring |
| Policy Code | CPB 0472 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Cardiology, Heart Failure Management, Hypertension Management, Cardiac Electrophysiology, Transplant Medicine |
| Key Action | Confirm every CPT 93701 claim maps to one of six approved indications and that documentation proves standard assessments were insufficient before ordering the test |
Aetna Thoracic Electrical Bioimpedance Coverage Criteria and Medical Necessity Requirements 2025
The central rule in CPB 0472 Aetna is a two-part gate. First, standard tools — medical history, physical exam, and standard assessment tools — must be insufficient to answer the clinical question. Second, the treating physician must document that thoracic electrical bioimpedance hemodynamic data are necessary for appropriate management.
Both conditions must be met. Meeting only one will not satisfy Aetna's medical necessity standard, and a claim without documentation of both is a claim denial waiting to happen.
Once those two gates are cleared, CPT 93701 (bioimpedance, thoracic, electrical) is covered for six specific indications. These are not suggestions — they are the complete list of covered uses under this coverage policy. If your ordering physician's clinical question doesn't map to one of these six, the service is not covered.
The six approved indications are:
| # | Covered Indication |
|---|---|
| 1 | Differentiating cardiogenic from pulmonary causes of acute dyspnea. This is one of the strongest use cases for thoracic electrical bioimpedance billing. The hemodynamic data helps distinguish whether a patient's breathlessness is cardiac or pulmonary in origin when standard workup is unclear. |
| 2 | Evaluation for transplant rejection in heart transplant patients — as a predetermined alternative to myocardial biopsy. This one has a critical documentation wrinkle. If a biopsy is ultimately performed after the thoracic electrical bioimpedance study, the physician must document why the biopsy was still medically necessary despite the non-invasive monitoring. Miss that note and you've created a denial risk on both the bioimpedance claim and the biopsy claim. |
| 3 | Monitoring response to medication changes in drug-resistant hypertension. The word "drug-resistant" matters here. Routine hypertension monitoring does not qualify. The documentation needs to support that standard antihypertensive therapy has failed and hemodynamic data is guiding medication adjustments. |
| 4 | Optimization of atrio-ventricular (AV) interval in members with AV sequential cardiac pacemakers. This is a narrow, well-defined indication. Your electrophysiology team should know it. If you see CPT 93701 coming through from an EP lab, verify the pacemaker indication is in the record. |
| 5 | Optimization of fluid management in congestive heart failure (CHF). This is likely your highest-volume use case. CHF fluid management is a common clinical scenario, but "common" doesn't mean the documentation burden goes away. You still need evidence that standard assessment tools were insufficient. |
| 6 | Outpatient monitoring of continuous inotropic therapy in terminal CHF. This is the most specific CHF indication. "Terminal CHF" and "continuous inotropic therapy" are both required. A CHF patient on intermittent inotropes or a patient not in a terminal stage does not fit this indication. |
Prior authorization requirements are not explicitly detailed within the CPB 0472 policy text. That said, given the documentation-heavy nature of this coverage policy, check with your Aetna provider relations contact or your contract to confirm whether prior auth is required for CPT 93701 in your market. Don't assume it isn't required.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Differentiation of cardiogenic vs. pulmonary causes of acute dyspnea | Covered | CPT 93701 | Standard assessment must be documented as insufficient |
| Transplant rejection evaluation — heart transplant, as predetermined alternative to biopsy | Covered | CPT 93701 | If biopsy is subsequently performed, document separate medical necessity for biopsy |
| Monitoring medication response in drug-resistant hypertension | Covered | CPT 93701 | "Drug-resistant" required — routine hypertension does not qualify |
| AV interval optimization in AV sequential pacemaker patients | Covered | CPT 93701 | Narrow indication — confirm pacemaker type in documentation |
| Fluid management optimization in CHF | Covered | CPT 93701 | Must document that standard tools were insufficient |
| Outpatient monitoring of continuous inotropic therapy in terminal CHF | Covered | CPT 93701 | Both "terminal CHF" and "continuous inotropic therapy" required |
| Any use outside the six approved indications | Not Covered | CPT 93701 | Claim denial expected if indication is absent or undocumented |
Aetna Thoracic Electrical Bioimpedance Billing Guidelines and Action Items 2025
Here's what your billing team needs to do before September 26, 2025:
| # | Action Item |
|---|---|
| 1 | Audit your active CPT 93701 claims and charge capture templates now. Pull every CPT 93701 encounter billed to Aetna in the last 90 days. Check that each maps to one of the six covered indications. If you find claims without clear indication-level documentation, flag them for your clinical team before the effective date. |
| 2 | Update your charge capture intake forms to capture both documentation requirements. Every CPT 93701 order for an Aetna member needs two things in the chart: (a) documentation that standard assessment tools were insufficient, and (b) the treating physician's statement that thoracic electrical bioimpedance hemodynamic data are necessary for management. Build a hard stop into your intake workflow if you can. |
| 3 | Create a separate documentation checklist for the heart transplant rejection indication. This indication is the most documentation-intensive. If a biopsy follows the bioimpedance study, your team needs to ensure the physician documents why the biopsy was still necessary. Without that note, you risk a denial on CPT 47135 (liver allotransplantation is listed as a related procedure in CPB 0472 — confirm transplant billing workflows with your compliance officer to understand how the policy applies across transplant types). |
| 4 | Confirm the distinction between terminal CHF and standard CHF in your documentation workflows. These are two different covered indications with different requirements. "Optimization of fluid management" applies broadly to CHF patients. "Outpatient monitoring of continuous inotropic therapy" requires terminal CHF specifically. Your coders need to understand the difference to select the right supporting diagnosis codes. |
| 5 | Verify prior authorization requirements with Aetna before September 26, 2025. CPB 0472 does not explicitly state a prior auth requirement, but Aetna's administrative requirements vary by plan and market. Confirm with your provider relations rep whether prior authorization is required for CPT 93701 in each Aetna product you bill — commercial, Medicare Advantage, and Exchange plans may differ. |
| 6 | Check reimbursement rates for CPT 93701 under your Aetna fee schedule. Policy modifications sometimes coincide with fee schedule updates. Pull your current contracted rate for CPT 93701 and verify it hasn't changed alongside CPB 0472. A change in coverage criteria without a corresponding fee schedule review is a common source of unexpected reimbursement shortfalls. |
The real risk here is documentation gaps, not denial of the technology itself. Aetna isn't saying thoracic electrical bioimpedance doesn't work. They're saying they'll only pay for it when physicians document that they needed it specifically, in a specific clinical situation, and that less expensive tools didn't give them the answer. That's a defensible standard — but only if your documentation process is airtight.
If your practice has high CHF or transplant volume, talk to your compliance officer before September 26. The documentation requirements in CPB 0472 are specific enough that a spot audit of your records now will cost you less than a retrospective denial recovery effort later.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Thoracic Electrical Bioimpedance Under CPB 0472
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 93701 | CPT | Bioimpedance, thoracic, electrical |
Other CPT Codes Listed in CPB 0472
These codes appear in the policy document as related codes. CPT 0358T is listed in the context of electrical bioimpedance-based monitoring. CPT 47135 is listed as a related procedure. Neither is listed as covered under the same six indications as CPT 93701 — confirm coverage status for each with Aetna directly before billing them together.
| Code | Type | Description | Group |
|---|---|---|---|
| 0358T | CPT (Category III) | Bioelectrical impedance analysis whole body composition assessment, with interpretation and report | Electrical bioimpedance-based monitoring (related) |
| 47135 | CPT | Liver allotransplantation, orthotopic, partial or whole, from cadaver or living donor, any age | Related CPT code listed in CPB 0472 |
Key ICD-10-CM Diagnosis Codes
CPB 0472 lists 192 ICD-10-CM codes. The full list includes malignant neoplasms (C00.0–C96.9) and benign neoplasms of the digestive system (D12.0–D13.x range). The full code set is available in the source policy at app.payerpolicy.org/p/aetna/0472.
A representative sample from the policy data:
| Code | Description |
|---|---|
| C00.0–C96.9 | Malignant neoplasms (full range) |
| D12.0–D12.9 | Benign neoplasm of colon, rectum, anus and anal canal |
| D13.0–D13.9 | Benign neoplasm of other and ill-defined parts of digestive system |
A note on the ICD-10 list: The breadth of diagnosis codes in CPB 0472 — including neoplasm codes — is notable for a cardiac monitoring policy. This may reflect the policy's application across complex patients with comorbid malignancies or transplant-related diagnoses. If your claim population includes cancer patients with cardiac complications, verify which diagnosis codes Aetna accepts as primary or secondary for CPT 93701. Your billing guidelines should map each covered indication to the appropriate supporting ICD-10-CM codes. If the ICD-10 code pairings in your charge capture don't align with this list, you're adding unnecessary claim denial risk.
Get the Full Picture for CPT 93701
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.